Table 6 lists the correlation between antiPeg11, IGF2AS, MEG3, SOX2ot, and Zeb2NAT expression levels in serum and the clinical characteristics of BRAF-mutated advanced melanoma patients treated with vemurafenib. Here, BRAF is linked to melanoma.